Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 2010

View Archived Issues

EpiCept's crolibulin enters phase I/II trial in anaplastic thyroid cancer

Preliminary phase I data presented on TAK-285 in advanced cancer

ABT-806 enters phase I trial in EGFR-expressing advanced solid tumors

Serodus licenses RO-1160367 from Roche

Trophos to lead MitoCare consortium to study cardioprotective agent TRO-40303

Ocera Therapeutics completes two studies of OCR-002

AstraZeneca divulges novel ligands of androgen receptor

New HIV integrase inhibitors discovered at Boehringer Ingelheim

ACY-1215/bortezomib combination shows promise in models of multiple myeloma

Preclinical study in MM shows activity of GNE-652 and synergism with GDC-0941

Selective JAK-2 inhibitor BMS-911543 enters clinic as myelofibrosis therapy

Tivozanib/paclitaxel combination is well tolerated by patients with metastatic breast cancer

Xention's new company Provesica to handle OAB program

Lundbeck, Zenobia and Vernalis to codevelop dardarin inhibitors

Ipsen discontinues development of BIM-23A760

New diaza heterocyclic agents identified at Mallinckrodt

Adimab to collaborate with Lilly, Genentech and Human Genome Sciences

E.C. approves sunitinib malate for treatment of pancreatic neuroendocrine tumors

Novartis withdraws application to extend Zometa indication in E.U.

Palau Pharma begins phase II trial of UR-63325 for allergic respiratory diseases

Concert Pharma patents new PEGylated azapeptide derivatives

Amgen identifies novel inhibitors of PI3K-alpha and/or mTOR

SciClone stops development of SCV-07 in chronic HCV infection based on phase IIb data

Provectus begins phase IIc trial of PH-10 in psoriasis

Jennerex and Transgene begin JX-594 trial in metastatic colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...